ArticleOncoimmunology
Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.Journal for immunotherapy of cancer · 2019Trial
- Article
- Human Papillomavirus-Related Cancer Vaccine Strategies.Vaccines · 2024Review
- Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.Advanced healthcare materials · 2024Review
- Innovations in Molecular Biomarkers and Biomaterial-Based Immunotherapies for Head & Neck Cancer.Current surgery reports · 2024Review
- Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.Frontiers in immunology · 2024Review
- HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus-associated cancers.iMeta · 2023Article
- HPV-positive murine oral squamous cell carcinoma: development and characterization of a new mouse tumor model for immunological studies.Journal of translational medicine · 2023Article
- Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies.Tissue engineering. Part C, Methods · 2023Review
- Review
- Review
- The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations.Oral oncology · 2022Review
- The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy.Frontiers in oncology · 2022Review
- Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.Oncoimmunology · 2021Article
- Myeloid-Derived Suppressor Cells in Immune Microenvironment Promote Progression of Esophagogastric Junction Adenocarcinoma.Frontiers in oncology · 2021Article
- The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.Cancer immunology, immunotherapy : CII · 2020Article
- HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING.The Journal of clinical investigation · 2020Article
- Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.International journal of biological sciences · 2020Review
- Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.Theranostics · 2020Article
- Drug-Mimicking Nanofibrous Peptide Hydrogel for Inhibition of Inducible Nitric Oxide Synthase.ACS biomaterials science & engineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
Abstract
Immunotherapeutic treatments in head and neck cancer clinical trials include cancer vaccines targeting foreign viral antigens or mutational neoantigens derived from cancer-expressed proteins. Anti-tumor immune responses place cancer cells under selective pressure to lose or downregulate target antigens; therefore, vaccination against virus- or host- "driver" oncogenes are proposed as a strategy to overcome immune escape. Herein, we demonstrate the impact of immunogenic viral antigens on anti-tumor response and immune editing in MOC2-E6E7, a syngeneic murine oral cancer cell line expressing HPV-16 E6 and E7 oncoproteins. Using orthotopic syngeneic models, we observed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.